Axsome Therapeutics (AXSM) announced that SYMBRAVO is now available by prescription in the United States for the acute treatment of migraine with or without aura in adults. SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that targets multiple brain pathways underlying a migraine attack. SYMBRAVO rapidly provides migraine pain freedom and returns patients to normal functioning at 2 hours versus placebo, with lasting pain freedom sustained from 2 to 24 hours in some patients after a single dose.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Positive Outlook for Axsome Therapeutics Despite Regulatory Setback, Driven by Promising Pipeline and Market Potential
- Axsome Therapeutics: Overcoming AXS-14 Setback with Strategic Focus on AXS-05
- Axsome Therapeutics Shareholders Approve Key Proposals at Meeting
- Axsome’s AXS-14 gets regulatory setback with RTF, says Morgan Stanley
- Axsome Therapeutics’ Growth Prospects Remain Strong Despite FDA Setback on AXS-14
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue